ARTICLE | Clinical News
AXS-05: Phase III started
March 28, 2016 7:00 AM UTC
Axsome began the double-blind Phase III STRIDE-1 trial to compare oral AXS-05 vs. bupropion in about 300 MDD patients who failed 1-2 antidepressant treatments. Patients will receive bupropion for 6 we...